首頁 > 市場調查報告書 > 醫療設備

整形外科

市場調查報告書

商品編碼

2048217

黏度補充療法市場－全球產業規模、佔有率、趨勢、機會、預測：按產品類型、最終用途、地區和競爭格局分類，2021-2031年

Viscosupplementation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By End Use By Region & Competition, 2021-2031F

出版日期: 2026年05月25日 | 出版商:

TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

全球關節內粘稠補充療法市場預計將從 2025 年的 51.5 億美元成長到 2031 年的 84.6 億美元，複合年成長率達到 8.62%。

關節內粘稠補充療法是一種主要用於治療骨關節炎的醫療程序，其原理是將透明質酸注射到關節腔內，以恢復關節的自然彈性並減輕疼痛。該市場的擴張主要受全球人口快速老化以及由此導致的退化性關節疾病增加的推動，而這些疾病需要有效的非手術治療方法。此外，患者越來越傾向於選擇可以延緩整形外科手術的微創療法，這也促進了對這類產品的需求。例如，根據英國關節炎協會（Versus Arthritis）報告，到2025年，英國將有超過2,000萬人患有肌肉骨骼疾病，凸顯了該領域巨大的疾病負擔。

市場概覽
預測期	2027-2031
市場規模：2025年	51.5億美元
市場規模：2031年	84.6億美元
複合年成長率：2026-2031年	8.62%
成長最快的細分市場	醫院
最大的市場	亞太地區

玻尿酸注射市場成長的主要障礙在於其保險報銷環境的不一致性和限制性，不同醫療體系之間的差異尤其顯著。監管機構和保險公司經常審查這些治療方法的臨床療效和成本效益，導致保險覆蓋範圍有限，患者自付費用高昂，從而限制了患者的就醫途徑，降低了整體市場滲透率。

市場促進因素

全球關節內粘稠補充療法市場正經歷根本性的重組，策略性重心正轉向單劑量療法，以兼顧患者的便利性和臨床療效。醫療機構正日益採用只需單次給藥的交聯透明質酸製劑，從而減少患者就診次數，並最大限度地降低多劑量帶來的風險。這種向高分子量單劑量療法發展的趨勢與該細分市場的強勁成長直接相關。 Bioventus公司2024年第四季及整個會計年度疼痛管理部門的兩位數銷售成長便印證了這一點，這主要得益於其單劑量產品Durolane的強勁表現。這種應用模式凸顯了整個產業正在向最佳化整形外科診療資源、同時提高患者治療依從性的治療方法轉變。

同時，肥胖率的飆升正加速退化性關節疾病的發生，成為市場擴張的關鍵催化劑。超重會對負重關節造成過大的機械壓力，導致軟骨快速磨損。因此，需要採用關節內粘稠補充療法等非手術干預措施來延緩侵入性手術。根據世界肥胖聯盟發布的《2025年世界肥胖地圖集》，預計2030年，全球成年人肥胖人口將達到11.3億。生活方式相關關節疾病患者群體的不斷成長，推動了對有效疼痛管理方案的需求，這體現在主要市場參與者的財務業績上，例如，某製藥公司在2024會計年度其製藥業務部門的銷售額同比成長了6.1%。

市場挑戰

全球關節內粘稠補充療法市場成長面臨的主要障礙之一是透明質酸注射的報銷機制限制性強且不一致。保險公司和監管機構經常從成本效益的角度審查這些關節內治療的臨床療效，往往導致嚴格的承保政策或直接拒付。這種嚴格的財務限制直接將負擔轉嫁給患者，導致患者需承擔高額的自付費用，使得許多患者難以負擔治療費用。因此，即使有臨床需求，但因無力支付治療費用而被迫放棄治療的患者，最終導致市場滲透率下降。

儘管需求不斷成長，但這些經濟限制嚴重阻礙了市場滲透。例如，根據關節炎基金會的報告，到2024年，美國將有超過3,250萬成年人患有骨關節炎。儘管如此龐大的患者群體需要非手術治療，但由於缺乏持續的保險支持，市場未能有效利用這一群體。因此，疾病盛行率與治療費用之間的差距限制了產生收入，並阻礙了該行業的整體擴張。

市場趨勢

隨著皮質類固醇和玻尿酸聯合聯合治療的日益普及，市場格局正在重塑。這種療法能夠為患者提供即時的疼痛緩解和持續的黏彈性改善。這一趨勢有效地消除了單一黏彈性替代劑起效延遲的常見問題，並透過雙重作用機制提高了患者的滿意度和依從性。市場參與者正積極拓展其國際產品系列，以滿足此需求。例如，Anika Therapeutics公司報告稱，其2024年商業通路收入成長了17%，這主要得益於其國際骨關節炎疼痛管理業務的強勁表現，該業務銷售的聯合產品「Cingal」便是這一成長的主要驅動力。

同時，為了最大限度地降低禽類蛋白過敏的風險並確保產品純度的穩定性，製藥業正果斷轉向使用非動物性生物發酵透明質酸原料。這項轉變將使製造商能夠在滿足全球監管機構日益嚴格的安全標準的同時，以高效擴大生產規模。領先的製藥公司正大力投資研發，以最佳化這些生物技術生產流程並拓展產品系列。例如，Fidia Pharmaceutici 在 2025 年 5 月的新聞稿中指出，該公司在上一會計年度投資 2,930 萬歐元用於研發，以支援其創新產品線，包括推進其專有的透明質酸技術平台的發展。

The Global Viscosupplementation Market is set to grow from USD 5.15 Billion in 2025 to USD 8.46 Billion by 2031, achieving an 8.62% CAGR. Viscosupplementation is a medical procedure that involves injecting hyaluronic acid into synovial joints to restore natural viscoelasticity and reduce pain, primarily for osteoarthritis. This market expansion is largely driven by the rapidly aging global population and a concurrent increase in degenerative joint diseases, which necessitate effective non-surgical management. Furthermore, a growing patient preference for minimally invasive therapies that can postpone orthopedic surgery also fuels demand for these products. For instance, Versus Arthritis reported that in 2025, over 20 million people in the United Kingdom lived with a musculoskeletal condition, underscoring the substantial disease burden driving this sector.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 5.15 Billion
Market Size 2031	USD 8.46 Billion
CAGR 2026-2031	8.62%
Fastest Growing Segment	Hospitals
Largest Market	Asia Pacific

A significant hurdle hindering market growth is the inconsistent and restrictive reimbursement landscape for hyaluronic acid injections across different healthcare systems. Regulatory bodies and insurers frequently scrutinize the clinical efficacy of these treatments against their cost, often resulting in limited insurance coverage and high out-of-pocket expenses, which in turn restrict patient access and reduce overall market penetration.

Market Driver

The Global Viscosupplementation Market is being fundamentally reshaped by a strategic shift toward single-injection regimens, addressing both patient convenience and clinical efficiency. Healthcare providers are increasingly adopting cross-linked hyaluronic acid formulations that require only one administration, thereby reducing clinic visits and minimizing risks associated with multi-dose courses. This preference for high-molecular-weight, single-shot therapies directly correlates with robust segment growth, as evidenced by Bioventus's double-digit revenue growth in its Pain Treatments vertical in Q4 and FY 2024, primarily driven by its single-injection Durolane product. Such adoption patterns underscore a broader industry pivot towards treatments that optimize orthopedic practice resources while enhancing patient adherence to therapy.

Simultaneously, escalating obesity rates are acting as a critical catalyst for market expansion by accelerating the onset of degenerative joint diseases. Excess body mass imposes severe mechanical load on weight-bearing joints, causing rapid cartilage erosion that necessitates non-surgical intervention like viscosupplementation to delay invasive procedures. According to the World Obesity Federation's 'World Obesity Atlas 2025', the global number of adults living with obesity is projected to reach 1.13 billion by 2030. This expanding demographic of patients with lifestyle-induced joint disorders is fueling demand for effective pain management solutions, reflected in the financial performance of key market players like Seikagaku Corporation, which saw its Pharmaceutical business segment sales increase 6.1% year-on-year in fiscal 2024.

Market Challenge

A critical barrier impeding the growth of the Global Viscosupplementation Market is the restrictive and inconsistent reimbursement landscape for hyaluronic acid injections. Insurance providers and regulatory bodies frequently scrutinize the clinical efficacy of these intra-articular treatments in relation to their costs, often leading to stringent coverage policies or outright payment denials. This financial stringency shifts the burden directly to patients, resulting in substantial out-of-pocket expenses that make the therapy economically inaccessible for many individuals. Consequently, the market experiences reduced adoption rates, as patients who cannot afford the procedure are compelled to forgo treatment despite its clinical necessity.

This economic limitation severely constrains market penetration, even amid increasing demand. For example, the Arthritis Foundation reported that in 2024, over 32.5 million adults in the United States were affected by osteoarthritis. Despite this vast patient population requiring non-surgical management, the lack of consistent insurance support prevents the market from effectively leveraging this volume. As a result, the disparity between disease prevalence and treatment affordability restricts revenue generation and hinders the overall expansion of the sector.

Market Trends

The market is being reshaped by the increasing adoption of combination therapies that feature corticosteroids and hyaluronic acid, providing patients with immediate pain relief along with sustained viscoelastic improvement. This trend effectively addresses the delayed onset of action often seen with standalone viscosupplements, thus improving patient satisfaction and compliance through a dual-mechanism approach. Market players are actively capitalizing on this demand by expanding their international portfolios of these hybrid formulations. For example, Anika Therapeutics reported a 17% increase in Commercial Channel revenue in 2024, significantly driven by the strong performance of its International OA Pain Management segment, which markets the combination product Cingal.

Concurrently, the industry is making a decisive shift towards non-animal derived, bio-fermented hyaluronic acid sources to minimize the risks of avian protein allergies and ensure consistent product purity. This transition enables manufacturers to scale production efficiently while meeting the stricter safety profiles mandated by global regulatory bodies. Leading pharmaceutical companies are heavily investing in research to optimize these biotechnological manufacturing processes and broaden their product portfolios. Fidia Farmaceutici, for instance, invested €29.3 million in R&D during the fiscal year to support its innovation pipeline, including advancements in its proprietary hyaluronic acid technology platform, as stated in its May 2025 press release.

Key Market Players

Sanofi SA
Seikagaku Corporation
Smith & Nephew PLC.
Lifecore Biomedical, LLC.
Fidia Farmaceutici S.p.A
F.Hoffmann-La Roche Ltd.
LG Life Sciences Ltd.
Ferring Pharmaceutical B.V.
Zimmer Biomet Holdings Inc
Anika Therapeutics, Inc.

Report Scope

In this report, the Global Viscosupplementation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Viscosupplementation Market, By Product Type

Single Injection
Three Injection
Five Injection

Viscosupplementation Market, By End Use

Hospitals
Orthopedic Clinics/ASCs

Viscosupplementation Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Viscosupplementation Market.

Available Customizations:

Global Viscosupplementation Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Viscosupplementation Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Product Type (Single Injection, Three Injection, Five Injection)
- 5.2.2. By End Use (Hospitals, Orthopedic Clinics/ASCs)
- 5.2.3. By Region
- 5.2.4. By Company (2025)
5.3. Market Map

6. North America Viscosupplementation Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Product Type
- 6.2.2. By End Use
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Viscosupplementation Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Product Type
    - 6.3.1.2.2. By End Use
- 6.3.2. Canada Viscosupplementation Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Product Type
    - 6.3.2.2.2. By End Use
- 6.3.3. Mexico Viscosupplementation Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Product Type
    - 6.3.3.2.2. By End Use

7. Europe Viscosupplementation Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Product Type
- 7.2.2. By End Use
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Viscosupplementation Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Product Type
    - 7.3.1.2.2. By End Use
- 7.3.2. France Viscosupplementation Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Product Type
    - 7.3.2.2.2. By End Use
- 7.3.3. United Kingdom Viscosupplementation Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Product Type
    - 7.3.3.2.2. By End Use
- 7.3.4. Italy Viscosupplementation Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Product Type
    - 7.3.4.2.2. By End Use
- 7.3.5. Spain Viscosupplementation Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Product Type
    - 7.3.5.2.2. By End Use

8. Asia Pacific Viscosupplementation Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Product Type
- 8.2.2. By End Use
- 8.2.3. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Viscosupplementation Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Product Type
    - 8.3.1.2.2. By End Use
- 8.3.2. India Viscosupplementation Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Product Type
    - 8.3.2.2.2. By End Use
- 8.3.3. Japan Viscosupplementation Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Product Type
    - 8.3.3.2.2. By End Use
- 8.3.4. South Korea Viscosupplementation Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Product Type
    - 8.3.4.2.2. By End Use
- 8.3.5. Australia Viscosupplementation Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Product Type
    - 8.3.5.2.2. By End Use

9. Middle East & Africa Viscosupplementation Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Product Type
- 9.2.2. By End Use
- 9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Viscosupplementation Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Product Type
    - 9.3.1.2.2. By End Use
- 9.3.2. UAE Viscosupplementation Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Product Type
    - 9.3.2.2.2. By End Use
- 9.3.3. South Africa Viscosupplementation Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Product Type
    - 9.3.3.2.2. By End Use

10. South America Viscosupplementation Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Product Type
- 10.2.2. By End Use
- 10.2.3. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Viscosupplementation Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Product Type
    - 10.3.1.2.2. By End Use
- 10.3.2. Colombia Viscosupplementation Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Product Type
    - 10.3.2.2.2. By End Use
- 10.3.3. Argentina Viscosupplementation Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Product Type
    - 10.3.3.2.2. By End Use

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Viscosupplementation Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Sanofi SA
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Seikagaku Corporation
15.3. Smith & Nephew PLC.
15.4. Lifecore Biomedical, LLC.
15.5. Fidia Farmaceutici S.p.A
15.6. F.Hoffmann-La Roche Ltd.
15.7. LG Life Sciences Ltd.
15.8. Ferring Pharmaceutical B.V.
15.9. Zimmer Biomet Holdings Inc
15.10. Anika Therapeutics, Inc.